Norway · Delayed Price · Currency is NOK ContextVision AB Earnings Call Transcripts
Fiscal Year 2025
-
Transformation to quantitative imaging progressed, with new clinical products launched and first patient enrolled in a data quality study. Q4 revenue declined 7.3% year-over-year due to FX, but market stabilization and a strong cash position support continued investment.
-
Revenue declined 21% year-over-year in Q3 due to market headwinds and FX impacts, but strategic progress continued in both Image and Data Quality. Strong cash position and new product launches support confidence in long-term growth.
-
Q2 2025 saw a 10% revenue decline to SEK 28.6 million, impacted by FX headwinds and market uncertainty. Key milestones included new partnerships, a major software upgrade, and a strong cash position of SEK 70 million, supporting continued investment and product launches.
-
Revenue fell 24% year-over-year to SEK 26.3 million, with adjusted EBITDA at SEK 2.1 million and a strong cash position of SEK 70 million. Key milestones include a major partnership with the University of Washington and expanded collaborations in data and image quality.
Fiscal Year 2024
-
Q4 delivered record revenue and strong EBITDA margin, driven by new product launches and OEM collaborations. A share buyback and a new partnership with the University of Washington highlight strategic moves, while a robust cash position supports future growth.
-
Q3 2024 saw net sales decline 8.1% year-over-year to SEK 30.1 million, mainly due to last year's non-recurring sales, while adjusted EBITDA margin remained strong at 37.9%. Investments in product development and organizational growth continue, with a key partnership expected by year-end.
-
Q2 net sales reached SEK 31.7 million with a 6% year-over-year decline, but recurring license revenue showed organic growth. Strategic investments in POCUS and new customer wins in Asia and North America support a stable outlook, with a strong cash position enabling continued expansion.